Citations

Mayo Clinic

Clear

1413 citation(s) found for "Wu, Kathryn".

Soft tissue aneurysmal bone cyst presenting as an enlarging neck mass: Case report and review of the head and neck literature
Chan, Stephen A. , Benson, John C. , Wittich, Michelle A. Neben, Chatzopoulos, Kyriakos , García, Joaquín J. , Geiersbach, Katherine B. , Gruber, Lucinda , Wermers, Robert A. , Pignolo, Robert J. , Rose, Peter S. , Abel, Kathryn M. Van , Neben Wittich, Michelle A, Van Abel, Kathryn M , Benson, John , Geiersbach, Katherine

The Neuroradiology Journal | August 6, 2024 | Volume: 38 | Issue: 3 | Pages: 377-381

10.1177/19714009241269441 | PMID 39106298 Get It

Soft tissue aneurysmal bone cysts (STABCs) are rare neoplasms histopathologically identical to aneurysmal bone cysts. These benign lesions are characterized by thin, peripheral ossification and no skeletal continuity. STABC may be difficult to distinguish from myositis ossificans (MO) and malignant entities from imaging and fine needle aspiration, due to rarity and overlapping features. We present a case of a STABC occurring in the paraspinal cervical muscles. The imaging, histopathology, molecular analysis, and treatment are discussed. Four other published cases of STABC of the head and neck are reviewed.
Gender gap in cardiothoracic surgery randomized controlled trial and post-hoc analysis of randomized controlled trial authorship from 2014 to 2020
Shariff, Mariam , Kumar, Ashish, Stulak, John M., Naumann, Kathryn E, Saddoughi, Sahar A. , Blackmon, Shanda H, Shariff, Mariam , Blackmon, Shanda

European Journal of Cardio-Thoracic Surgery | August 5, 2024 | Volume: 66 | Issue: 4 | Pages: No page available

10.1093/ejcts/ezae297 | PMID 39110508 Get It

Abstract OBJECTIVES To estimate gender disparities among first and last authorships in cardiothoracic randomized controlled trials (RCTs) and association of gender with publications in high-impact journals. METHODS PubMed/MEDLINE database was searched from 1 January 2014 to 31 December 2020 using R statistical software via the ‘easyPubMed’ package to retrieve pertinent data. The ‘gender’ package was utilized to determine gender using the United States Social Security Administration Baby Name Data. The percentage of female first and last authors were computed along with determining the uniqueness of the names. The association of gender and publication in high-impact peer-reviewed journals was delineated. Jonckheere’s trend was computed. RESULTS The database search retrieved a total of 4820 RCTs, of which gender was encoded for the first author in 3247 (67%) RCTs, among which 911 (28%) studies had women as first authors, with a similar trend across 7 years (P = 0.23). Gender was encoded for the last author of 3204 (66%) RCTs, of which 622 (19%) studies had women as last authors, with a similar trend across 7 years (P = 0.45). A total of 627 studies were published in high-impact-factor journals, among which 79 (16%) studies had female first authors and 67 (13%) studies had female last authors. CONCLUSIONS There is an obvious gender disparity of first and last authors in cardiothoracic surgery-related RCTs, with a similar trend across 7 years. However, the post-hoc analysis did demonstrate a positive trend with an increase in the number of female first authors, demonstrating progress.
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia
Li, Zhenhua , Gocho, Yoshihiro , Yang, Wenjian , Crews, Kristine R. , Lee, Shawn H.R. , Roberts, Kathryn G. , Mullighan, Charles G. , Relling, Mary V. , Yu, Jiyang , Loh, Mignon L. , Saygin, Caner , Litzow, Mark R. , Karol, Seth E. , Inaba, Hiroto , Konopleva, Marina , Paietta, Elisabeth, Evans, William E. , Yang, Wenjian , Crews, Kristine R , Roberts, Kathryn G , Mullighan, Charles G , Relling, Mary V , Yu, Jiyang , Yeoh, Allen E J , Loh, Mignon L , Litzow, Mark R. , Jeha, Sima , Karol, Seth E , Inaba, Hiroto , Pui, Ching-Hon , Konopleva, Marina , Jain, Nitin , Stock, Wendy , Jabbour, Elias , Kornblau, Steven M , Yang, Jun J.J. , Yoshimura, Satoshi , Yeoh, Allen Eng Juh , Stock, Wendy , Jabbour, Elias , Kornblau, Steven M.

Journal of Clinical Oncology | August 5, 2024 | Volume: 42 | Issue: 29 | Pages: 3478-3490

10.1200/jco.24.00500 | PMID 39102629 Get It

PURPOSE Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a strikingly higher cure rate in children compared with adults. However, the pharmacological basis of age-related differences in ALL treatment response remains unclear. METHODS Studying 767 children and 309 adults with newly diagnosed B-cell ALL enrolled on frontline trials at St Jude Children's Research Hospital, MD Anderson Cancer Center, the Alliance for Clinical Trials in Oncology, and the ECOG-ACRIN Cancer Research Group, we determined the ex vivo sensitivity of leukemia cells to 21 drugs. Twenty-three ALL molecular subtypes were identified using RNA sequencing. We systematically characterized the associations between drug response and ALL genomics in children, adolescents and young adults, and elderly adults. We evaluated the effect of age-related gene expression signature on ALL treatment outcomes. RESULTS Seven ALL drugs (asparaginase, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and inotuzumab ozogamicin) showed differential activity between children and adults, of which six were explained by age-related differences in leukemia molecular subtypes. Adolescents and young adults showed similar patterns of drug resistance as older adults, relative to young children. Mercaptopurine exhibited subtype-independent greater sensitivity in children. Transcriptomic profiling uncovered subclusters within CRLF2 -, DUX4 -, and KMT2A -rearranged ALL that were linked to age and cytotoxic drug resistance. In particular, a subset of children had adult-like ALL on the basis of leukemia gene expression patterns across subtypes, despite their chronological age. Resistant to cytotoxic drugs, children with adult-like ALL exhibited poor prognosis in pediatric ALL trials, even after adjusting for age and minimal residual diseases. CONCLUSION Our results provide pharmacogenomic insights into age-related disparities in ALL cure rates and identify leukemia prognostic features for treatment individualization across age groups.
Single Construct Suppression and Replacement Gene Therapy for the Treatment of All CALM1 -, CALM2 -, and CALM3 -Mediated Arrhythmia Disorders
Hamrick, Samantha K. , Kim, C.S. John, Tester, David J. , Gencarelli, Manuela , Tobert, Kathryn E. , Gluscevic, Martina, Ackerman, Michael J. , Kim, C.S. John

Circulation: Arrhythmia and Electrophysiology | July 29, 2024 | Volume: 17 | Issue: 8 | Pages: No page available

10.1161/circep.123.012036 | PMID 39069900 Get It

BACKGROUND: CaM (calmodulin)-mediated long-QT syndrome is a genetic arrhythmia disorder (calmodulinopathies) characterized by a high prevalence of life-threatening ventricular arrhythmias occurring early in life. Three distinct genes ( CALM1 , CALM2 , and CALM3 ) encode for the identical CaM protein. Conventional pharmacotherapies fail to adequately protect against potentially lethal cardiac events in patients with calmodulinopathy. METHODS: Five custom-designed CALM1 -, CALM2 -, and CALM3 -targeting short hairpin RNAs (shRNAs) were tested for knockdown (KD) efficiency using TSA201 cells and reverse transcription-quantitative polymerase chain reaction. A dual-component suppression and replacement (SupRep) CALM gene therapy (CALM-SupRep) was created by cloning into a single construct CALM1 -, CALM2 -, and CALM3-specific shRNAs that produce KD (suppression) of each respective gene and a shRNA-immune CALM1 cDNA (replacement). CALM1-F142L, CALM2-D130G, and CALM3-D130G induced pluripotent stem cell-derived CMs were generated from patients with CaM-mediated long-QT syndrome. A voltage-sensing dye was used to measure action potential duration at 90% repolarization (APD90). RESULTS: Following shRNA KD efficiency testing, a candidate shRNA was identified for CALM1 (86% KD), CALM2 (71% KD), and CALM3 (94% KD). The APD90 was significantly prolonged in CALM2-D130G (647±9 ms) compared with CALM2-WT (359±12 ms; P <0.0001). Transfection with CALM -SupRep shortened the average APD90 of CALM2-D130G to 457±19 ms (66% attenuation; P <0.0001). Additionally, transfection with CALM -SupRep shortened the APD90 of CALM1-F142L (665±9 to 410±15 ms; P <0.0001) and CALM3-D130G (978±81 to 446±6 ms; P <0.001). CONCLUSIONS: We provide the first proof-of-principle suppression-replacement gene therapy for CaM-mediated long-QT syndrome. The CALM-SupRep gene therapy shortened the pathologically prolonged APD90 in CALM1 -, CALM2 -, and CALM3-variant CaM-mediated long-QT syndrome induced pluripotent stem cell-derived CM lines. The single CALM-SupRep construct may be able to treat all calmodulinopathies, regardless of which of the 3 CaM-encoding genes are affected.
Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma
Cheraghlou, Shayan , Christensen, Sean R. , Walker, Joanna, Ferrándiz‐Pulido, Carla , Bibee, Kristin , Carter, Joi B., Samie, Faramarz H. , Carroll, Bryan T. , Vidimos, Allison T. , Baum, Christian L. , Leitenberger, Justin J. , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S. , Carr, David R. , Shahwan, Kathryn T. , Stevenson, Mary L. , Bordeaux, Jeremy S. , Srivastava, Divya , Patel, Vishal Anil , Carucci, John A. , Carr, David R.

JAMA Dermatology | July 24, 2024 | Volume: 160 | Issue: 9 | Pages: 989

10.1001/jamadermatol.2024.2242 | PMID 39046711 Get It

ImportanceCutaneous squamous cell carcinoma (CSCC) is the second most common malignant disease in the US. Although it typically carries a good prognosis, a subset of CSCCs are highly aggressive, carrying regional and distant metastatic potential. Due to its high incidence, this aggressive subset is responsible for considerable mortality, with an overall annual mortality estimated to equal or even surpass melanoma. Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology and outcomes. Therefore, the bulk of the CSCC literature is composed of single-center and multi-institutional retrospective cohort analyses. Given variations in reporting measures and analyses in these studies, interpretability between studies and the ability to pool results are limited.ObjectiveTo define standardized reporting measures for retrospective CSCC studies.FindingsAn expert panel was convened to determine standardized guidelines for recording and analyzing retrospective CSCC data. A total of 13 dermatologists and dermatologic surgeons with more than 5 years of posttraining experience and considerable experience with performing CSCC outcomes research were recruited to the panel. Consensus recommendations were achieved for CSCC retrospective study reporting measures, definitions, and analyses.Conclusions and RelevanceThe recommendations in this report present the potential to standardize future CSCC retrospective studies. With such standardization, future work may have greater interstudy interpretability and allow for pooled analyses.
Neonatal intestinal colonization of Streptococcus agalactiae and the multiple modes of protection limiting translocation
Greenfield, Kara G , Harlow, Olivia S., Witt, Lila T. , Dziekan, Evelyn M. , Tamar, Christian , Meier, Josephine, Brumbaugh, Jane E. , Levy, Emily R. , Knoop, Kathryn A. , Tamar, Christian R , Levy, Emily R , Knoop, Kathryn A , Brumbaugh, Jane E

Gut Microbes | July 23, 2024 | Volume: 16 | Issue: 1 | Pages: No page available

10.1080/19490976.2024.2379862 | PMID 39042143 Get It

A Multiomics, Molecular Atlas of Breast Cancer Survivors
Bauer, Brent A. , Schmidt, Caleb M., Ruddy, Kathryn J. , Meydan, Cem , Schmidt, Julian C., Smith, S. , Couch, Fergus J., Earls, John C. , Dudley, Joel T. , Mason, Christopher E. , Zhang, Bodi, Phipps, Stephen M., Schmidt, Michael A. , Dudley, Joel T , Mason, Christopher E , Schmidt, Michael A , Meydan, Cem , Olson, Janet E. , Price, Nathan D.

Metabolites | July 22, 2024 | Volume: 14 | Issue: 7 | Pages: 396

10.3390/metabo14070396 | PMID 39057719 Get It

Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims.
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program
Penrice, Daniel D. , Hara, Kamalpreet S. , Chara, Beatriz Sordi , Kezer, Camille A. , Schmidt, Kathryn A. , Kassmeyer, Blake , Lennon, Ryan J. , Rosedahl, Jordan K., Roellinger, Daniel , Rattan, Puru , Williams, Katherine, Leuenberger, Angela , Kamath, Patrick S. , Shah, Vijay H. , Sordi Chara, Beatriz , Kezer, Camille , Schmidt, Kathryn, Lennon, Ryan, Rosedahl, Jordan, Kloft-Nelson, Sara, Kamath, Patrick S , Simonetto, Douglas A , Penrice, Daniel , Lennon, Ryan J. , Kloft‐Nelson, Sara M. , Simonetto, Douglas A.

Hepatology Communications | July 22, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000498 | PMID 39037370 Get It

Background: Remote patient monitoring (RPM) is an emerging focus in health care, and specialized programs may reduce medical costs, supplement in-office visits, and improve patient satisfaction. In this study, we describe the development, feasibility, and early outcomes of an RPM program for patients with decompensated cirrhosis. Methods: Forty-six patients were offered enrollment at the time of hospital discharge in the cirrhosis RPM program (CiRPM), of which 41 completed at least 30 days of monitoring. Participants were mailed remote monitoring equipment and a tablet to be used for patient-reported outcomes. Alerts were continuously monitored by virtual nursing staff who could perform targeted interventions. A cohort of historical controls (n = 74) was created for comparison using inverse probability of treatment weighting. Results: Patients were enrolled in the program for a mean of 83.9 days, with 28 (68%) completing the full 90-day program. Participants uploaded vital signs and responded to symptom-based questionnaires on 93% of the monitored days. On end-of-program surveys, over 75% of patients expressed satisfaction with the program. Gender, age, and MELD-Na were similar between CiRPM and weighted control groups. The 90-day readmission rate was 34% in CiRPM and 47% in weighted controls. In the CiRPM group, 12% of subjects had 2 or more admissions, compared to 37% in the weighted control group. Conclusion: This study demonstrates the feasibility of a cirrhosis-specific RPM program. Overall, patient satisfaction and utilization of the CiRPM was high. Future studies are needed to confirm the impact of RPM on the reduction of hospital readmissions in decompensated cirrhosis.
The right educational environment: Oral tolerance in early life
Cheifetz, Talia Raitt, Knoop, Kathryn A. , Cheifetz, Talia R, Knoop, Kathryn A

Immunological Reviews | July 13, 2024 | Volume: 326 | Issue: 1 | Pages: 17-34

10.1111/imr.13366 | PMID 39001685 Get It

Summary Oral tolerance promotes the suppression of immune responses to innocuous antigen and is primarily mediated by regulatory T cell (Tregs). The development of oral tolerance begins in early life during a “window of tolerance,” which occurs around weaning and is mediated by components in breastmilk. Herein, we review the factors dictating this window and how Tregs are uniquely educated in early life. In early life, the translocation of luminal antigen for Treg induction is primarily dictated by goblet cell‐associated antigen passages (GAPs). GAPs in the colon are negatively regulated by maternally‐derived epidermal growth factor and the microbiota, restricting GAP formation to the “periweaning” period (postnatal day 11–21 in mice, 4–6 months in humans). The induction of solid food also promotes the diversification of the bacteria such that bacterially‐derived metabolites known to promote Tregs—short‐chain fatty acids, tryptophan metabolites, and bile acids—peak during the periweaning phase. Further, breastmilk immunoglobulins—IgA and IgG—regulate both microbial diversity and the interaction of microbes with the epithelium, further controlling which antigens are presented to T cells. Overall, these elements work in conjunction to induce a long‐lived population of Tregs, around weaning, that are crucial for maintaining homeostasis in adults.